Published in Leuk Res on June 27, 2008
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology (2009) 1.75
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leuk Lymphoma (2012) 1.61
Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma (2012) 1.54
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs (2011) 1.27
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol (2012) 1.12
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res (2009) 1.09
A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. Blood (2009) 0.97
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology (2014) 0.96
Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol (2014) 0.90
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica (2011) 0.88
Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Leukemia (2013) 0.83
Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity. PLoS One (2015) 0.82
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2012) 0.80
Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Semin Immunopathol (2011) 0.78
Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. J Immunol (2016) 0.77
Recent advances and novel treatment paradigms in acute lymphocytic leukemia. Ther Adv Hematol (2016) 0.75
The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis (2013) 0.75
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms. J Immunol (2017) 0.75
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood (2005) 8.37
Clinical staging of chronic lymphocytic leukemia. Blood (1975) 7.29
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet (2007) 6.29
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol (2007) 2.99
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 2.64
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood (2004) 2.39
Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology (1999) 1.94
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood (2003) 1.57
Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer (2001) 1.48
Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol (2004) 1.20
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol (2005) 1.16
Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res (2004) 1.00
Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma (2006) 0.95
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Systematic review of depression, anxiety, and other indicators of psychological distress among U.S. and Canadian medical students. Acad Med (2006) 5.82
Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study. JAMA (2006) 5.06
Relationship between burnout and professional conduct and attitudes among US medical students. JAMA (2010) 4.34
Burnout and suicidal ideation among U.S. medical students. Ann Intern Med (2008) 3.96
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol (2006) 3.83
Association of resident fatigue and distress with perceived medical errors. JAMA (2009) 3.70
Prevalence of alcohol use disorders among American surgeons. Arch Surg (2012) 3.53
Medical student distress: causes, consequences, and proposed solutions. Mayo Clin Proc (2005) 3.46
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Personal life events and medical student burnout: a multicenter study. Acad Med (2006) 2.98
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. Am J Hematol (2009) 2.84
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol (2003) 2.72
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
The effects of work-hour limitations on resident well-being, patient care, and education in an internal medicine residency program. Arch Intern Med (2005) 2.63
Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol (2007) 2.50
Burnout among U.S. medical students, residents, and early career physicians relative to the general U.S. population. Acad Med (2014) 2.47
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Quality of life, burnout, educational debt, and medical knowledge among internal medicine residents. JAMA (2011) 2.37
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol (2012) 2.36
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood (2007) 2.31
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol (2008) 2.29
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood (2008) 2.18
A multicenter study of burnout, depression, and quality of life in minority and nonminority US medical students. Mayo Clin Proc (2006) 2.14
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood (2003) 2.12
How do distress and well-being relate to medical student empathy? A multicenter study. J Gen Intern Med (2007) 2.10
The Impact of Stigma and Personal Experiences on the Help-Seeking Behaviors of Medical Students With Burnout. Acad Med (2015) 2.06
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma (2007) 1.92
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol (2014) 1.92
Relationship between work-home conflicts and burnout among American surgeons: a comparison by sex. Arch Surg (2011) 1.90
Stress and burnout among surgeons: understanding and managing the syndrome and avoiding the adverse consequences. Arch Surg (2009) 1.89
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
Patterns of distress in US medical students. Med Teach (2011) 1.87
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood (2010) 1.83
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood (2010) 1.80
The learning environment and medical student burnout: a multicentre study. Med Educ (2009) 1.79
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res (2002) 1.79
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood (2010) 1.79
Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol (2002) 1.76
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood (2009) 1.75
Physician satisfaction and burnout at different career stages. Mayo Clin Proc (2013) 1.75
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood (2004) 1.71
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.71
Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood (2002) 1.70
Impact of resident well-being and empathy on assessments of faculty physicians. J Gen Intern Med (2009) 1.65
Personal consequences of malpractice lawsuits on American surgeons. J Am Coll Surg (2011) 1.64
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood (2002) 1.63
Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol (2007) 1.63
Burnout and serious thoughts of dropping out of medical school: a multi-institutional study. Acad Med (2010) 1.63
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma (2008) 1.61
Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood (2009) 1.61
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leuk Lymphoma (2012) 1.61